Mark Robson

53PUBLICATIONS
571CO-AUTHORS
Environmental epidemiologyCancer geneticsCancer therapy (excl. chemotherapy and radiation therapy)Decision makingCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|May 05, 2026
Benralizumab for Eosinophil-Related Cutaneous Adverse Events of Anticancer Therapy: A Phase II Trial.

|Mar 04, 2026
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer.

Anton Safonov, Minna Lee, David N Brown

|Jan 28, 2026
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.

Nadine M Tung, Mark E Robson, Tianyu Li

|Dec 17, 2025
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy.

Hope S Rugo, David W Cescon, Mark E Robson

|Nov 26, 2025
The Impact of Breast Cancer Polygenic Risk Score Disclosure on Decisional Conflict Around Risk-Reducing Mastectomy in BRCA1/2 Carriers.

Giulia Ongaro, Caroline Salafia, Rania Sheikh

|Oct 23, 2025
Prospective Study of Annual Whole-Body Magnetic Resonance Imaging as Part of a Multimodality Screening Program for Individuals With Li-Fraumeni Syndrome.

Asaf Maoz, Nan Chen, Puja Umaretiya

Pageof 9

Frequent Collaborators

13 joint publications

Yelena M Kemel

11 joint publications

Michael Walsh

10 joint publications

David B Solit

9 joint publications

Michael F Berger